Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Tofacitinib helped regrow hair in a patient with severe hair loss and improved their quality of life without side effects.

This letter discusses the limited treatment options for pediatric alopecia areata and the lack of controlled studies for therapies like systemic and off-label immunosuppressive drugs, without reporting new clinical results.

This study compared oral tofacitinib and methotrexate in treating moderate-to-severe alopecia areata, finding that tofacitinib was more effective at reducing SALT scores and improving scalp hair assessment PRO scores, though both treatments reduced psychological distress similarly without serious adverse effects.

This report discusses Titanflow as a potential improvement in male urinary health by focusing on the detrusor muscle rather than prostate size, suggesting it may offer relief where other supplements have limited effectiveness.

This study observed that temporal triangular alopecia in infants presents with distinct clinical and dermatoscopic features, indicating the usefulness of dermatoscopy for diagnosis and differential diagnosis.

In this case report, a young adult male with resistant alopecia areata showed nearly 90% hair regrowth after 3 months of treatment with tofacitinib, alongside biotin supplementation, without any side effects observed.

This study suggests that thymosin beta 4 may regulate hair growth by influencing VEGF and MMP-2 levels through the Wnt/β-catenin/Lef-1 signaling pathway in mouse models.

This case study documented a 36-year-old woman with postpartum-onset frontal fibrosing alopecia who showed significant improvement in hair regrowth after early combination therapy with dutasteride, tofacitinib, and intralesional triamcinolone acetonide, suggesting potential benefits of multimodal treatment in this typically irreversible condition.

This study found that deleting transferrin receptor 1 in specific mouse tissues led to varied lethal outcomes, demonstrating its diverse roles beyond iron uptake.

This study found that mice with a disrupted TGFα gene display a curly whisker-coat phenotype, similar to waved-1 mice, suggesting TGFα's crucial role in skin architecture and hair development.

This study in Mexican adolescents with severe alopecia areata reported that oral tofacitinib treatment resulted in hair growth and reduced alopecia severity without serious adverse effects.

This study found that oral tofacitinib led to variable hair regrowth in patients with resistant alopecia areata, implying that longer treatment durations may be needed to fully assess its effectiveness.

This review discusses the use of Tisseel for stabilizing particulate grafts and reports no new clinical results; the authors emphasize the need for further controlled trials.

In this case report, researchers identified a potential adverse skin reaction, called SDRIFE or Baboon syndrome, caused by the drug tofacitinib in a 19-year-old woman being treated for alopecia subtotalis, leading the authors to recommend discontinuation of the drug.

This study demonstrated that the Turing bifurcation, typically a pitchfork bifurcation under zero-flux conditions, becomes transcritical under fixed boundary conditions, highlighting the importance of considering boundary condition variations in morphogenetic analyses.

This case report describes a young Indian boy with resistant alopecia areata who experienced nearly complete hair regrowth within 5 months of treatment with oral tofacitinib.

This study suggests that trichohyalin is modified by peptidyl-arginine deiminase before being cross-linked by TGase 3, allowing the formation of rigid structures in hair follicle cells.

This review discusses treatment options for trichotillomania, focusing on cognitive-behavioral interventions and promising developments in combined pharmacotherapy and therapy approaches, but reports no new findings.

This article discusses the potential of oral tofacitinib as a treatment for atopic dermatitis, alopecia areata, and vitiligo, without presenting new clinical results.

This study reports that tofacitinib, a JAK 1/3 inhibitor, showed significant improvement in a patient with co-occurring severe alopecia totalis and lichen planus hypertrophicus, conditions that are typically resistant to treatment.

This paper reviews the challenges of treating alopecia areata affecting eyelashes and discusses the risks associated with traditional therapies; it reports no new clinical results.

This article proposes a broad interpretation of tissue engineering as systematically controlling the body's cells, matrices, and fluids, suggesting many existing therapies may fall under this category.

This study proposed that the tiger tail phenomenon in trichothiodystrophy hair is caused by regular undulations of hair fibers, altering the optical properties seen under polarized light.

In this study, TASP0382088 showed potent selective inhibition of the ALK5 receptor, significantly reducing Smad2 phosphorylation in mouse skin following topical application.

This study found that tectoridin, an isoflavone from Rhizoma Belamcandae, may stimulate hair growth by activating Wnt signaling in human and mouse cell cultures.

This study found that among adults with severe alopecia areata, alopecia totalis, or alopecia universalis, oral tofacitinib was more effective than methotrexate in reducing hair loss over a 12-week period, though long-term safety and efficacy remain unestablished.

This report suggests that tofacitinib may be beneficial for patients with nail disease unresponsive to other treatments.

This study reviewed the efficacy of mechanical fractionation techniques to produce tissue stromal vascular fraction (tSVF) and found that tSVF injections are particularly effective for conditions like osteoarthritis and wound healing, with centrifugation before fractionation improving isolation efficiency regardless of preparation method.

Tofacitinib citrate improved nail dystrophy and pain in patients with alopecia universalis without causing side effects.